Trevi Therapeutics to Participate in Upcoming September Conferences

Core Viewpoint - Trevi Therapeutics, Inc. is advancing its investigational therapy Haduvio™ for chronic cough associated with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC) [1][4]. Company Overview - Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing Haduvio™ (oral nalbuphine ER) for chronic cough treatment [4]. - Haduvio is the first investigational therapy to demonstrate a statistically significant reduction in cough frequency in clinical trials for patients with IPF chronic cough and RCC [4]. Market Context - Chronic cough affects up to 85% of patients with IPF, with approximately 150,000 patients in the U.S. suffering from this condition [5]. - Patients with chronic cough may cough up to 1,500 times per day, leading to severe impacts on their quality of life and potential disease progression [5]. - There are currently no approved therapies for chronic cough in IPF patients, and existing off-label treatments offer minimal benefits [5]. Refractory Chronic Cough - RCC, affecting around 2-3 million patients in the U.S., is characterized by a persistent cough lasting more than 8 weeks despite treatment for underlying conditions [6]. - The condition is associated with significant social and economic burdens, including complications like urinary incontinence and sleep disruption [6]. Upcoming Conferences - Trevi Therapeutics will participate in several healthcare conferences in September 2025, including the Wells Fargo Healthcare Conference and the Morgan Stanley Global Healthcare Conference [2][3].